Stopping GLP-1 drugs can quickly erase cardiovascular benefits

Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, approximately one in eight U.S. adults now take these medications, which also provide cardiovascular ...

Vaping: Emerging harms health systems can't ignore

When e-cigarettes first appeared around 2010, they were hailed as a breakthrough: nicotine delivery without the toxic tar and combustion byproducts of traditional cigarettes. Public health bodies cautiously endorsed them ...

page 4 from 40